Figure 1. (a) Multiple areas of reddish-brown pigmentation can be seen on the patient’s face, with ill-defined margins on the face, some coalescing into patches. (b) After eight cycles of the RVD regimen (rituximab, bortezomib and dexamethasone), the patient’ cutaneous rash showed significant improvement along with the systemic improvement of CD. CD: Castleman disease.
Figure 2. (a) Lymphoid cell infiltration around the skin appendages (H&E stain, × 40). (b) High-power view showed most of cells are mature plasma cells (H&E stain, × 100). (c) CD138 staining showed the infiltration of (small clusters) of plasma cells (immunohistochemistry, × 200). H&E: hematoxylin and eosin.
Figure 3. (a) Low-power view showed lymph follicles of varying size with a retained mantle zone and a diffuse expansile infiltrate of basophilic cells in the paracortical regions (H&E stain, × 40). (b) High-power view showed diffuse plasma cell hyperplasia extending to the subcapsular region of the lymph node (H&E stain, × 200). (c) High-power view showed a slightly atrophic follicle with thickening of the mantle zone (H&E stain, × 200). (d) MUM1 staining showed diffuse plasma cell hyperplasia (immunohistochemistry, × 40). H&E: hematoxylin and eosin.